These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20044209)

  • 21. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.
    Neta R; Oppenheim JJ; Douches SD
    J Immunol; 1988 Jan; 140(1):108-11. PubMed ID: 2447166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
    Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
    Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
    Rosenman J
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioprotective effect of moderate wine consumption in patients with breast carcinoma.
    Morganti AG; Digesù C; Panunzi S; De Gaetano A; Macchia G; Deodato F; Cece MG; Cirocco M; Di Castelnuovo A; Iacoviello L; Valentini V; Cellini N; de Gaetano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1501-5. PubMed ID: 19395196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for the administration of amifostine.
    Schuchter LM
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future directions in toxicity prevention.
    Brizel DM
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):17-20. PubMed ID: 9794997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head and neck squamous cell carcinoma: optimizing the therapeutic index.
    Rosenthal DI; Blanco AI
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):501-14. PubMed ID: 16001957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiotherapy: emerging treatment improvement strategies.
    Milas L; Mason KA; Liao Z; Ang KK
    Head Neck; 2003 Feb; 25(2):152-67. PubMed ID: 12509799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new administration schedule for amifostine as a radioprotector in cancer therapy.
    Wagner W; Radmard A; Schönekaes KG
    Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of pentoxifylline as a modifier of radiation therapy.
    Nieder C; Zimmermann FB; Adam M; Molls M
    Cancer Treat Rev; 2005 Oct; 31(6):448-55. PubMed ID: 16225996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro.
    Millar BC; Bell JB; Millar JL; Treleaven J; Montes A; Joffe JK; Powles RL; McElwain TJ
    Exp Hematol; 1992 Feb; 20(2):209-15. PubMed ID: 1371966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
    Page AV; Liles WC
    Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cytoprotective effects of amifostine in the treatment of tumors].
    Burkon P; Petýrek P; Spurný V
    Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.